GENEVA—Two thirds of patients with advanced non-small cell lung cancer that had failed first line anti-EGFR therapy responded to a new drug: AZD9291 according to findings discussed at the European Lung Cancer Conference. Pasi Jänne MD PhD from the Dana-Farber Cancer Institute in Boston MA, Director of the Lowe Center for Thoracic Oncology and Professor of Medicine at Harvard Medical School, gave Oncology Times reporter Peter Goodwin the latest details about the clinical potential of this therapy.
You may also like...
Adjuvant Chemotherapy Extends Life in Locally Advanced Bladder Cancer 13 Mar, 2015 ‘Rescanning’ Optimizes Pencil Beam Proton Delivery to Moving Lung Tumor 12 May, 2015 Targeting Emerging Drugable Pathways in Breast Cancer—Clinical Potential Assessed 28 Mar, 2015 Deep Genomic Profiling in Breast Cancer Promises to Improve Outcomes 26 Mar, 2015
- Previous story CD8+ Cell Infiltration for Prognosis in Non-Small Cell Lung Cancer; Checkpoint Inhibition 2nd/3rd-line in Mesothelioma
- Next story Growing Evidence that Anti BRAF Melanoma Drugs Benefit Some Patients with Non-Small Cell Lung Cancer
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014